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FIGURE 2. Histologic findings of the explanted heart showing an
extremely thin left ventricular wall with marked fibrosis (elastica van
Gieson’s stain).
Case Reportsfunction. Furthermore, an exercise stress test showed
increased left VAD flow even at a fixed pump speed. Frazier
et al2 used a calf model in which both native ventricles were
excised and replaced with 2 continuous-flow VADs. An ex-
ercise test demonstrated increased flow in both VADs.2 Our
results have confirmed their experimental findings, suggest-
ing that even without native ventricular contraction, biven-
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imply the possibility of clinical use of continuous-flow arti-
ficial hearts currently being tested in animal models.
When implanting 2 rotary pumps for biventricular support,
concern exists about a flow imbalance between the pulmo-
nary and systemic circulation. After the implant operation,
the systemic and pulmonary vascular resistances become dy-
namic and are further influenced by use of inotropes, discon-
tinuation of mechanical ventilation, and other factors. These
altered hemodynamic states could exacerbate the flow imbal-
ance during the perioperative period, especially in patients
with a noncontractile heart. In the present case, the first extu-
bation failed owing to severe pulmonary congestion caused
by right VAD overflow.3 Interestingly, after resolution of
these perioperative hemodynamic fluxes, the management
became easier, with no additional pulmonary congestion
noted. A natural flow balance appears to be achieved by the
autoregulatory properties of continuous-flow VADs.4
The currently available pulsatile total artificial hearts
have numerous restrictions. We believe that the present
successful case will promote the clinical use of rotary blood
pumps in patients with biventricular failure for bridging
and, even, destination therapy.
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Nadir Tafer, MD,a and Alexandre Ouattara, MD, PhD,a,d,e Bordeaux and Pessac, FranceThe ventricular assist device (VAD), as a bridge to heart
transplantation, is being increasingly used in patients of
all ages who are experiencing refractory heart failure. In
these patients, massive bleeding remains a leading and
challenging complication. Among the possible causes, the
occurrence of acquired von Willebrand disease (avWD)
has been reported in adult patients.1 Indeed, the loss of
high-molecular-weight (HMW) von Willebrand factor
(vWF) multimers because of shear stress, similar to that
seen in aortic stenoses,1 is frequently observed in patients
with axial flow in a left VAD.2,3ery c October 2013
FIGURE 1. Bleeding and allogenic transfusions. Quantification of
bleeding, and red blood cell (RBC) counts and plasma requirements,
after implantation of a biventricular assist device. Arrows, Surgical
re-explorations; D, postoperative day.
Case ReportsTo treat bleeding associated with avWD, various thera-
pies, including reduced anticoagulation, the control of local
bleeding, and plasma or platelet transfusions, are used.
However, none of these therapies specifically address the
abnormalities seen in avWD, and the effectiveness of these
therapies remains uncertain. Herein, we describe the first
case of avWD in a pediatric patient after implantation
of a pulsatile biventricular assist device (BerlinHeart;
Berlin Heart GmBH, The Woodlands, Tex), which caused
severe perioperative bleeding but could be treated with
von Willebrand factor concentrate. The child was success-
fully bridged until heart transplantation.FIGURE 2. Normal plasma (lane 1) and plasma from our patient
receiving a biventricular assist device (lane 2). The dye front is at the
bottom of the discontinuous gel, and the large multimers are shown in
the upper part of the gel. Lane 1 indicates normal plasma; lane 2, plasma
from our patient who had lost high-molecular-weight multimers, as
indicated by the missing bands in the upper part of the gel (red circle).CASE REPORT
A 3-year-old, 13-kg boy, with a history of dilated
cardiomyopathy, had a biventricular assist device implanted
as a bridge until heart transplantation. The antithrom-
botic regimen consisted of only unfractionated heparin.
Four days after the device was implanted, a bleed of 5
mL$kg1$h1 occurred, which required surgical re-
exploration. A 700-mL red blood cell (RBC) transfusion
was also necessary. By day 5, a bleed of 2 mL$kg1$h1
persisted and required transfusion of 500 mL of RBCs,
270 mL of plasma, 110 mL of platelets, and further surgical
re-exploration. Despite these therapeutic measures,
bleeding recurred and required several surgical re-
explorations at 3-day intervals and allogenic transfusion
of 9490 mL of RBCs and 3620 mL of plasma (Figure 1).
Prothrombin time and fibrinogen levels were closely
monitored. ROTEM monitoring (Tem International GmbH,
M€unchen, Germany) showed an EXTEMclotting time value
of 66 seconds (normal range, 46-97 seconds), an EXTEM
clotting formation time value of 196 seconds (normal range,
41-109 seconds), an a angle of 62 (normal range, 69-82),
and maximal clot firmness of 43 mm (normal range, 52-70
mm). By day 20, the patient developed increasedThe Journal of Thoracic and Cahemorrhagic syndrome (9 mL$kg1$h1) with an increased
requirement for transfusion of 1740mL of RBCs, 895mL of
plasma, and 438 mL of platelets. Because bleeding was
severe, an infusion of tranexamic acid (3 mL$kg1$h1)
was given. The patient also received 3 doses (30 mg/kg) of
recombinant activated factor VII, although these were
unsuccessful (Novoseven; NovoNordisk, Princeton, NJ).
We also stopped heparin for 3 hours while heparin activity
was within normal limits (anti-Xa activity, 0.2-0.3 IU/mL).
Because avWDwas suspected, human vWF concentrates
of 80 IU/kg every 8 hours, associated with human factorrdiovascular Surgery c Volume 146, Number 4 e31
Case ReportsVIII (FVIII) concentrates of 40 IU/kg (Wilstart; LFB
Biomedicaments, Les Ulis, France) every 8 hours, were
started. Before giving these new therapies, blood was
collected for an assay. The following day, the daily require-
ment for RBC transfusion had decreased to 400 mL
(Figure 1). The results of the von Willebrand panel showed
that the vWF antigen (vWF:Ag) was normal (77% by
enzyme-linked immunosorbent assay; normal range,
50%-160%), as was factor VIII coagulant (62% vs normal
range, 60%-150%). Collagen-binding activity (vWF:CB)
was 58% by enzyme-linked immunosorbent assay (normal
range, 50%-150%), as was vWF ristocetin cofactor
(64% vs normal range, 60%-130%). The ratio of
vWF:CB/vWF:Ag was 0.75, which was also within the
normal range (0.70). Analysis of vWFmultimers revealed
an abnormal pattern, mainly characterized by a marked
decrease in HMW forms, which was compatible with
avWD (Figure 2). Because FVIII coagulant was normal,
only therapy with human vWF concentrate was continued
(Wilfactin; LFB Biomedicaments) and at the same dose.
At 72 hours after beginning this therapy, the child did not
require any further transfusion support until heart transplan-
tation could be performed (on day 29). There were no
thromboembolic complications. The postoperative course
was uneventful, and the patient left the intensive care unit
a week after heart transplantation.
DISCUSSION
To our knowledge, this is the first case of avWD to be
described in a child, although avWD has been previously
reported in adults after a VAD implantation. Heilmann
and colleagues4 analyzed patients with a pneumatic VAD
system or an axial flow pump for the presence of avWD
and for bleeding complications. They observed bleeding
episodes more frequently in VAD than in axial flow pump,
in the early and the late course. However, they did not report
any significant difference in the severity of the avWD. An
avWD results from shear stress in the pump itself and in
the tubes that connect the pump to the heart and great ves-
sels. This shear stress causes unfolding of the HMW multi-
mers of vWF with exposure of the D2 domains of the VWF
monomers and subsequent cleavage by the protease
ADAMTS-13.5 Bleeding phenomenon may be attributed
to the loss of large vWFmultimers, leading to abnormalities
in platelet adhesion at the sites of vascular injury. The
bleeding diatheses seen in these patients is out of proportion
to that expected with postsurgical anticoagulation, and has
been attributed to the additional hemostatic defect contrib-
uted by degradation of vWF.
In some patients, a loss or decrease of HMWmultimers is
the only laboratory abnormality. Various therapies, such ase32 The Journal of Thoracic and Cardiovascular Surgdesmopressin acetate, tranexamic acid, and control of local
bleeding, have been traditionally used to treat major
bleeding events during avWD. However, these therapies
do not specifically address the abnormalities observed
during avWD. Furthermore, the efficacy of these agents in
patients with avWD secondary to VAD is unknown. In
our case, many therapies, including recombinant FVIIa,
were used in association with large-volume blood and
plasma transfusions, but were ineffective. For this reason,
we tried a more specific strategy that focused on the missing
vWD factor.
Wilstart and Wilfactin (LFB Biomedicaments) are esta-
blished treatment options for patients with vWD but are
not usually prescribed for avWD. Before initiating this
treatment, a von Willebrand panel was conducted to obtain
values for vWF activity, vWF:Ag, and FVIII when bleeding
was the most abundant. An absence of high-molecular-
weight multimers was the only abnormal factor identified.
Because hemorrhagic syndrome was not controlled, we
wanted to provide the patient with the missing vWF. Once
treatment with Wilfactin was started, we observed a
significant decrease in the need for blood transfusions until
heart transplantation was conducted. The average daily cost
of this therapy was estimated at approximately V3210
(US$4220).
In conclusion, because avWD can also occur in children
with VAD, our approach should be considered every time
there is persistent bleeding. To our knowledge, we have
reported the first case of severe bleeding related to
avWD in a child supported with a bi-VAD and in whom
bleeding was stopped with the use of Wilfactin. Its use in
VAD-associated avWD has not been reported previously,
and this treatment should be explored further in children
with avWD.
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